Har­bour Bio­Med inks deal up to $395M; ORIC re­fines plans for two drugs

Plus, news about Idor­sia, Enve­da, Zymeworks, BerGen­Bio and Ig­no­ta Labs:

Har­bour Bio­Med does an­oth­er deal: The Shang­hai-based biotech’s sub­sidiary, called HBM Al­pha Ther­a­peu­tics, inked a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER